Table S2. Summary of gene expression profiles of NK101 and NK-92 by RNA-sequencing. (XLSX 2920âkb) (XLSX 2920 kb
Table S1. Target and NK cells treated with or without olaparib were analyzed for expression of cell ...
Table S1. Summary of NK cell expansion from 31 cancer patients (supplementary information of referen...
Additional file 1. Supplementary methods. Supplementary Figure 1. Clinicopathological features and D...
Table S1. Summary of adventitious agents screening in NK101 cell line (XLSX 11 kb
Figure S1.Histology of the primary biopsy specimens. Biopsied samples from brain lesion were stained...
Additional file 2: Table S2. List of clinical trials with engineered NK cell therapies. N = 53 clini...
A sub-network among 33 unique genes representing the hub, authority and high BC ranked vertices from...
Supplemental Table 1 provides a full list of differentially expressed (2-fold or greater) genes fr...
Additional file 4: Table S4. List of clinical trials with engineered combination NK cell therapies. ...
2a and 2b are entitled Functional analysis of the genes regulated in NK cells following FcR activati...
Additional file 3: Table S3. List of clinical trials with non-engineered combination NK cell therapi...
Additional file 1: Table S1. List of clinical trials with non-engineered NK cell therapies. N = 36 c...
quanTIseq signature matrix and used RNA-seq data from purified/enriched immune cells. RNA-seq data: ...
Table S1. Data description of TCGA RNA sequencing data. Table S2. List of antibody-drug conjugates. ...
Figure S1. MHC Class-I profile in K562, CAKI-1, SN12C, A498 and 786-O cells. The expression of MHC-I...
Table S1. Target and NK cells treated with or without olaparib were analyzed for expression of cell ...
Table S1. Summary of NK cell expansion from 31 cancer patients (supplementary information of referen...
Additional file 1. Supplementary methods. Supplementary Figure 1. Clinicopathological features and D...
Table S1. Summary of adventitious agents screening in NK101 cell line (XLSX 11 kb
Figure S1.Histology of the primary biopsy specimens. Biopsied samples from brain lesion were stained...
Additional file 2: Table S2. List of clinical trials with engineered NK cell therapies. N = 53 clini...
A sub-network among 33 unique genes representing the hub, authority and high BC ranked vertices from...
Supplemental Table 1 provides a full list of differentially expressed (2-fold or greater) genes fr...
Additional file 4: Table S4. List of clinical trials with engineered combination NK cell therapies. ...
2a and 2b are entitled Functional analysis of the genes regulated in NK cells following FcR activati...
Additional file 3: Table S3. List of clinical trials with non-engineered combination NK cell therapi...
Additional file 1: Table S1. List of clinical trials with non-engineered NK cell therapies. N = 36 c...
quanTIseq signature matrix and used RNA-seq data from purified/enriched immune cells. RNA-seq data: ...
Table S1. Data description of TCGA RNA sequencing data. Table S2. List of antibody-drug conjugates. ...
Figure S1. MHC Class-I profile in K562, CAKI-1, SN12C, A498 and 786-O cells. The expression of MHC-I...
Table S1. Target and NK cells treated with or without olaparib were analyzed for expression of cell ...
Table S1. Summary of NK cell expansion from 31 cancer patients (supplementary information of referen...
Additional file 1. Supplementary methods. Supplementary Figure 1. Clinicopathological features and D...